Maryland Capital Management’s Pacira BioSciences PCRX Stock Holding History

Maryland Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$310K	Hold	5,829	–	–	0.03%	181
2022 Q2	$340K	Buy	5,829 +1,339	+30%	+$87.7K	0.03%	178
2022 Q1	$343K	Buy	4,490 +107	+2%	+$7.13K	0.02%	194
2021 Q4	$264K	Buy	4,383 +479	+12%	+$26.4K	0.01%	232
2021 Q3	$219K	Buy	3,904 +391	+11%	+$22.5K	0.01%	237
2021 Q2	$213K	Sell	3,513 -557	-14%	-$35.3K	0.01%	248
2021 Q1	$285K	Buy	+4,070	New	+$291K	0.02%	205

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

SCM

Spyglass Capital Management San Francisco, California $1.41B AUM 7.96% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Maryland Capital Management's PCRX Position: Q3 2022 in Review

Maryland Capital Management held its Pacira BioSciences (PCRX) position steady in Q3 2022 at 5,829 shares worth $310K. The position accounts for 0.03% of the portfolio, ranked #181.

Maryland Capital Management first reported a position in PCRX in Q1 2021 and has held it in 7 quarters since. The position peaked at $343K in Q1 2022. 273 funds tracked by Wall St. Rank hold PCRX as of Q3 2022.

Maryland Capital Management held 5,829 shares of Pacira BioSciences worth $310K as of Q3 2022.
Maryland Capital Management left its Pacira BioSciences share count unchanged in Q3 2022.
Pacira BioSciences made up 0.03% of Maryland Capital Management's portfolio in Q3 2022, its #181 holding.
Maryland Capital Management first reported a position in Pacira BioSciences in Q1 2021 and has held it in 7 quarters since.
Maryland Capital Management's Pacira BioSciences position peaked at $343K in Q1 2022.
273 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2022.

Based on Maryland Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.